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Abstract: The increase in antibacterial resistance is a serious challenge for both the health and defence
sectors and there is a need for both novel antibacterial targets and antibacterial strategies. RNA
degradation and ribonucleases, such as the essential endoribonuclease RNase E, encoded by the rne
gene, are emerging as potential antibacterial targets while antisense oligonucleotides may provide
alternative antibacterial strategies. As rne mRNA has not been previously targeted using an antisense
approach, we decided to explore using antisense oligonucleotides to target the translation initiation
region of the Escherichia coli rne mRNA. Antisense oligonucleotides were rationally designed and
were synthesised as locked nucleic acid (LNA) gapmers to enable inhibition of rne mRNA translation
through two mechanisms. Either LNA gapmer binding could sterically block translation and/or LNA
gapmer binding could facilitate RNase H-mediated cleavage of the rne mRNA. This may prove to be
an advantage over the majority of previous antibacterial antisense oligonucleotide approaches which
used oligonucleotide chemistries that restrict the mode-of-action of the antisense oligonucleotide to
steric blocking of translation. Using an electrophoretic mobility shift assay, we demonstrate that the
LNA gapmers bind to the translation initiation region of E. coli rne mRNA. We then use a cell-free
transcription translation reporter assay to show that this binding is capable of inhibiting translation.
Finally, in an in vitro RNase H cleavage assay, the LNA gapmers facilitate RNase H-mediated mRNA
cleavage. Although the challenges of antisense oligonucleotide delivery remain to be addressed,
overall, this work lays the foundations for the development of a novel antibacterial strategy targeting
rne mRNA with antisense oligonucleotides.
Keywords: antibacterial; antisense oligonucleotide; gapmer; locked nucleic acid (LNA); RNase E;
RNase H; rne mRNA; translation blocking
1. Introduction
The emergence of both natural and engineered antimicrobial resistant strains of bacte-
ria poses a significant challenge to the health and defense sectors. Unfortunately, traditional
drug development programmes, that successfully provided the antibiotics of the 20th cen-
tury, are failing to keep pace with emerging resistance [1,2]. Consequently, there is a
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growing need for the development of novel antibacterial strategies that target alternative
pathways and/or have unconventional mechanisms of action.
RNA degradation pathways and ribonucleases (RNases), the enzymes responsible
for RNA turnover, have recently been identified as targets that could be exploited for
antibiotic development [3,4]. Specifically, the endoribonuclease RNase E, and the rne gene
that encodes it, are ideal candidates for antibacterial targeting for a number of reasons [3,4].
Firstly, RNase E/rne is essential [5–8] and so inhibitors of RNase E, or repressors of rne gene
expression, would be expected to have antibacterial activity. Furthermore, RNase E/rne is
implicated in bacterial virulence of the pathogens Salmonella enterica and Yersinia pestis [9,10].
Finally, RNase E/rne is highly conserved amongst Gram-negative bacteria but there is no
known human orthologue [3,11] suggesting that specific inhibitors or repressors would
target RNase E/rne-containing bacteria but not human hosts.
Some progress has been made in validating RNase E/rne as an antibacterial target
through the identification of small molecule inhibitors of RNase E, using structure-based
virtual high-throughput screening, and the characterisation of their inhibitory activity
in vitro. Through this approach, a number of small molecules have been identified that
inhibit RNase E from multiple bacterial pathogens in vitro [12,13]. However, the half maxi-
mal inhibitory concentration (IC50) for each of these inhibitors was in the low millimolar
range, much higher than would be desired for an effective antibiotic [12,13]. Even enhanced
inhibition, obtained using a combination of inhibitory small molecules, required millimolar
concentrations of inhibitors [12]. Therefore, while these small molecules have potential as
lead compounds for the development of antibiotics targeting RNase E, there is work still to
be done.
An alternative antibacterial strategy to using small molecule antibiotics is the de-
velopment of antisense oligonucleotide antibacterials reviewed in [14–17]. Antisense
oligonucleotides are short, single-stranded nucleic acid sequences that are complementary
to a target mRNA. They can down-regulate gene expression by binding to their target
mRNA and inhibiting its translation through the creation of a steric block to ribosome bind-
ing and/or by facilitating RNase H recruitment and RNA cleavage [14–17] (Supplementary
Figure S1). Typically, antisense oligonucleotides are synthesised from nucleotide analogues
(Supplementary Figure S2) in order to enhance the affinity for RNA and decrease the
susceptibility to cellular nucleases (reviewed in [14–18]). However, these chemical modifi-
cations can also negatively affect RNase H recruitment and limit the mode-of-action of the
antisense oligonucleotide to steric blocking of ribosome binding [17,18]. A key advantage
of the antisense approach is that it should be possible to rationally design an antisense
oligonucleotide to target any mRNA. If the target mRNA encodes an essential protein,
e.g., rne mRNA, then the antisense oligonucleotide may have antibacterial properties. A
number of antisense oligonucleotides, that target a variety of mRNAs, have been reported
to have antibacterial activity (see Supplementary Table S1 for examples).
In the current study we explored the potential of targeting rne mRNA with antisense
oligonucleotides as a possible alternative antibacterial strategy. To our knowledge, rne
mRNA has not been previously targeted using an antisense approach. We rationally de-
signed two oligonucleotide sequences to have complementarity to the translation initiation
region of Escherichia coli rne mRNA. Both sequences were synthesised as locked nucleic
acid (LNA) gapmers, oligonucleotides consisting of a central region of DNA flanked by
regions of chemically modified LNA nucleotides [18], with an LNA3-DNA10-LNA3 and an
LNA4-DNA8-LNA4 configuration. The ability of each of the four LNA gapmers to bind to
the translation initiation region of E. coli rne mRNA, inhibit translation, and recruit RNase
H to mediate mRNA cleavage, was evaluated in vitro using an electrophoretic mobility
shift assay (EMSA), a cell-free reporter assay and a gel-based RNase H cleavage assay, re-
spectively. All four of the LNA gapmers bound to the translation initiation region of E. coli
rne mRNA, inhibited translation and facilitated RNase H-mediated cleavage. However,
there were preferences with regard to the antisense oligonucleotide sequence/binding site
and gapmer configuration. These studies clearly demonstrate that it is possible to target
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rne mRNA with antisense oligonucleotides and they provide key knowledge that could be
taken forwards to develop a novel antibacterial strategy.
2. Results
2.1. Targeting E. coil rne with LNA Gapmers
The first step in investigating an antisense approach to potentially down-regulate rne
gene expression was to identify a region of the E. coli rne mRNA to target and rationally
design antisense oligonucleotides against it. Most bacterial antisense oligonucleotides
target the translation initiation region of an mRNA [17]. This is because this region of an
mRNA is usually unstructured and accessible to ribosomes meaning that it will likely also
be accessible to an antisense oligonucleotide [17]. In addition, antisense oligonucleotide
binding to this region of the mRNA is most likely to sterically block translation by prevent-
ing ribosome binding which may be more effective than a steric block aimed at halting
ribosome progression at a downstream binding site. Indeed, although E. coli rne mRNA
contains a long (361-nucleotide), highly structured 5′ UTR, the translation initiation region
has been reported to be unstructured [19]. Therefore we decided to target the translation
initiation region of E. coli rne mRNA with antisense oligonucleotides.
Next, we needed to select a suitable antisense oligonucleotide chemistry. Chemical
analogues that are commonly used in bacterial antisense oligonucleotide chemistry include
phosphorothioate, phosphorodiamidate morpholino (PMO), peptide nucleic acid (PNA)
and LNA (Supplementary Figure S2) [17,18]. Phosphorothioate has a reduced affinity for
RNA, compared to DNA, but phosphorothioate oligonucleotide:mRNA duplexes are recog-
nised by RNase H [17,18]. In contrast, PMO, PNA and LNA all have a significantly greater
affinity for RNA but neither PMO oligonucleotide:mRNA, PNA oligonucleotide:mRNA
nor LNA oligonucleotide:mRNA duplexes are recognised by RNase H [17,18]. The mode-
of-action of entirely PMO, PNA or LNA antisense oligonucleotides is therefore restricted
to steric blocking of translation. To overcome this possible limitation, gapmer antisense
oligonucleotides consisting of a central region of DNA flanked by chemically modified
nucleotides can be used [17,18]. The central DNA region of the gapmer facilitates RNase
H recruitment and mRNA cleavage while the flanking chemically modified nucleotides
provide the enhanced oligonucleotide stability and RNA binding affinity. In order to allow
us to compare both the steric blocking of ribosome binding and the RNase H-mediated
mRNA cleavage mode-of-action of antisense oligonucleotides, we decided to use LNA
gapmers to target rne mRNA. This strategy is shown schematically in Figure 1A.
Finally, we needed to rationally design our antisense oligonucleotide sequence and
decide on the LNA gapmer configurations to synthesise. Kurreck et al., found that LNA
gapmers with a central region of phosphorothioate DNA of at least seven nucleotides were
sufficient to facilitate recruitment of RNase H [20]. In addition, flanking LNA regions of
three nucleotides were sufficient to increase gapmer binding affinity for RNA and, together
with a phosphorothioate backbone, confer protection from nucleases [20]. Considering
these parameters, two 16-mer sequences, LNA gapmer A and LNA gapmer B, were
designed to be complementary to the translation initiation region of rne mRNA (Figure
1B). A non-complementary scrambled 16-mer sequence, Scrambled LNA gapmer, was also
designed to use as a control (Figure 1B). LNA gapmer A would be expected to occlude
both the ribosome binding site (RBS) and the start codon of the rne mRNA and would
be expected to prevent ribosome binding. LNA gapmer B would only be expected to
occlude the rne mRNA start codon. Binding of LNA gapmer B may, or may not, prevent
ribosome binding but it would be expected to block the progression of bound ribosomes.
Therefore comparing the activity of LNA gapmer A and LNA gapmer B may indicate
whether there is a preferred antisense oligonucleotide binding site within the rne mRNA
translation initiation region. Each LNA gapmer sequence was synthesised as an LNA3-
DNA10-LNA3 3-10-3 gapmer (LNA gapmer A1/B1 and Scrambled LNA gapmer) and as an
LNA4-DNA8-LNA4 4-8-4 gapmer (LNA gapmer A2/B2) (Figure 1B).
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Figure 1. Targeting the translation initiation region of rne mRNA with LNA gapmers. (A) An antisense
LNA gapmer comprising DNA (mauve) flanked by LNA (teal) binds to the translation initiation region
(including the ribosome binding site (RBS), gold) of rne mRNA (blue). This prevents the ribosome
(grey) from binding and sterically blocks translation. It also recruits RNase H (grey scissors) which
cleaves the rne mRNA to prevent RNase E synthesis. (B) LNA gapmer A and LNA gapmer B were
designed to be complementary to the translation initiation region of E. coli rne mRNA (blue; RBS,
gold; start codon, brown). Scrambled LNA gapmer, which is not complementary to the translation
initiation region of E. coli rne mRNA, was also designed. In each of the LNA gapmers, LNA bases
(teal/underlined) flank DNA bases (mauve). Each LNA gapmer was synthesised as an LNA3-DNA10-
LNA3 3-10-3 gapmer (LNA gapmer A1/B1 and Scrambled LNA gapmer). LNA gapmers A and B
were also synthesised as an LNA4-DNA8-LNA4 4-8-4 gapmer (LNA gapmer A2/B2).
2.2. The LNA Gapmers Bind to the Translation Initiation Region of E. coli rne mRNA
Having designed and synthesised LNA gapmers to target the translation initiation
region of E. coli rne mRNA, the next step was to determine if they could bind to E. coli
rne mRNA in vitro. We decided to use an EMSA to evaluate LNA gapmer binding. We
designed an unstructured 45-mer minimal E. coli rne mRNA corresponding to the −30 to
+15 translation initiation region of E. coli rne mRNA to use as the target RNA. This region of
E. coli rne mRNA has been reported to be unstructured in the context of the complete rne 5′
UTR [19] and we therefore reasoned that the unstructured minimal E. coli rne mRNA would
be a suitable RNA target for preliminary experiments. The minimal E. coli rne mRNA
was synthesised as a 3′ FAM-labelled oligonucleotide (Figure 2A) and incubated with an
increasing concentration of each of the LNA gapmers. The reaction mixtures were analysed
by native-PAGE (Figure 2B–D).
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Figure 2. LNA gapmers bind to the translation initiation region of E. coli rne mRNA. (A) 3′ FAM-
labelled 45-mer minimal E. coli rne mRNA (blue; RBS, gold; start codon, brown). (B–D) Representative
12% native-PAGE of minimal E. coli rne mRNA incubated with increasing concentrations of LNA
gapmer as described in Materials and Methods. (B) LNA gapmers A1 and A2. (C) LNA gapmers B1
and B2. (D) Scrambled LNA gapmer. The contrast in the images has been adjusted to aid visualisation.
The minimal E. coli rne mRNA was present at 50 nM, where indicated (+). The LNA gapmers were
present at the indicated concentration. The migration positions of the minimal E. coli rne mRNA
(mRNA) and the complex of the minimal E. coli rne mRNA and the LNA gapmer (mRNA:LNA
gapmer) are indicated (blue triangles). Plots of percentage minimal E. coli rne mRNA bound against
LNA gapmer concentration are shown in (B) LNA gapmers A1 and A2 and (C) LNA gapmers B1 and
B2. Data are the mean from three experimental repeats and error bars represent the standard error of
the mean (SEM). Data were fit (solid line) to a cooperative binding equation as described in Materials
and Methods.
LNA gapmers A1, A2, B1 and B2 all caused an electrophoretic mobility shift of the
minimal E. coli rne mRNA indicating that they all bound to the minimal E. coli rne mRNA
to form an mRNA:LNA gapmer complex (Figure 2B,C). In contrast, no mobility shift was
observed for minimal E. coli rne mRNA in the presence of Scrambled LNA gapmer, even
Molecules 2021, 26, 3414 6 of 15
at the highest concentration of LNA gapmer tested (500 nM) indicating that this LNA
gapmer did not bind the minimal E. coli rne mRNA (Figure 2D). Essentially all of the
minimal E. coli rne mRNA was present as an mRNA:LNA gapmer complex at LNA gapmer
concentrations of 50 nM and above for LNA gapmer A1 and LNA gapmer A2 (Figure 2B).
However, higher LNA gapmer concentrations of 250 nM and above were required for LNA
gapmer B1 and LNA gapmer B2 before all of the minimal E. coli rne mRNA was present
as an mRNA:LNA gapmer complex (Figure 2C). This suggests that the LNA gapmer A
sequence or binding site is preferred over the LNA gapmer B sequence or binding site. In
an attempt to quantify this observable difference, the data for LNA gapmers A1, A2, B1 and
B2 were fit to a cooperative binding equation (Figure 2B,C) and an apparent dissociation
constant (Kd) was calculated for each of these LNA gapmers. The apparent Kds for LNA
gapmers A1 and A2 (26.7 ± 4.9 nM and 18.4 ± 2.8 nM, respectively) were lower than the
apparent Kds for LNA gapmers B1 and B2 (38.3 ± 3.5 nM and 76.6 ± 7.4 nM, respectively)
supporting the qualitative observation that the LNA gapmer A sequence, or binding site,
is preferred over the LNA gapmer B sequence, or binding site.
2.3. The LNA Gapmers Inhibit Translation in an In Vitro Cell-Free Assay
In order to determine whether binding of the LNA gapmers to the translation initia-
tion region of E. coli rne mRNA can inhibit translation, an in vitro cell-free transcription-
translation system coupled with a luciferase assay was devised. This assay is shown
schematically in Figure 3A. A translational fusion of the −397 to +30 region of rne and the
coding region of the firefly luciferase (luc) gene (Supplementary Figure S3) was cloned into
pET28b to generate pET28[rne-luc]. An in vitro cell-free transcription-translation system
was then used to transcribe the rne-luc gene and translate it into luciferase. Since luciferase
converts luciferin into oxy-luciferin, emitting light in the process, the observed lumines-
cence can provide a readout of the relative level of rne-luc mRNA translation or the amount
of luciferase present. In the presence of an LNA gapmer, if the LNA gapmer binds to the
translation initiation region of rne mRNA and inhibits rne-luc mRNA translation, it would
be expected that less luciferase would be produced and the luminescence would be lower
than in the absence of LNA gapmer.
The in vitro cell-free assay was performed in the absence of LNA gapmer and in
the presence of 0.5 nM, 5 nM and 50 nM of each of the LNA gapmers (Figure 3B). All of
the LNA gapmers, including Scrambled LNA gapmer, which should not bind to rne-luc
mRNA, negatively affected the total luminescence emitted in a dose-dependent manner.
This suggests that the inclusion of any LNA gapmer in the reaction mixture may non-
specifically affect rne-luc translation and/or luciferase activity. However, at a concentration
of 50 nM LNA gapmer, the reduction in luminescence was significantly larger for LNA
gapmers A1 and A2 and LNA gapmers B1 and B2 than it was for Scrambled LNA gapmer.
This is most likely due to the ability of these LNA gapmers to specifically bind to the rne-luc
mRNA and sterically block its translation. LNA gapmers A1 and A2 appear to be more
potent inhibitors of translation than LNA gapmers B1 and B2 which is consistent with the
higher binding affinity for the translation initiation region of E. coli rne mRNA that was
observed in the EMSAs (Figure 2B,C). There is also some indication that the 4-8-4 gapmer
configuration is more effective than the 3-10-3 gapmer configuration for the LNA gapmer
B sequence, which may suggest that the additional LNA nucleotides enhance LNA gapmer
stability and/or target binding under these assay conditions.
2.4. The LNA Gapmers Stimulate RNase H-Mediated Cleavage of the Translation Initiation Region
of E. coli rne mRNA In Vitro
Having determined that the LNA gapmers are capable of binding to the translation
initiation region of E. coli rne mRNA and inhibiting translation of rne-luc mRNA in vitro,
presumably by sterically blocking translation, we next wanted to investigate whether they
could also recruit RNase H and stimulate RNase H-mediated cleavage of E. coli rne mRNA
(see Figure 1A for the expected mode-of-action). An in vitro RNase H cleavage assay was
developed in which the 3′ FAM-labelled 45-mer minimal E. coli rne mRNA (Figure 2A) was
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used as the target mRNA. The minimal E. coli rne mRNA was incubated with an increasing
concentration of each of the LNA gapmers in the presence of RNase H and the reaction
products were analysed by denaturing urea-PAGE (Figure 4).
Figure 3. An in vitro cell-free transcription-translation system, coupled with a luciferase assay. (A) A
schematic of the assay steps. A translational fusion of the −397 to +30 region of E. coli rne and the
coding region of the firefly luciferase (luc) gene (Supplementary Figure S3) was cloned into pET28b
to generate pET28[rne-luc]. (Left) An in vitro cell-free transcription-translation system transcribes the
rne-luc gene into RNA (orange; RBS, gold; start codon, brown) and the RNA is translated to produce
luciferase (orange wedge). Luciferase converts luciferin (dark green triangle) into oxy-luciferin
(light green triangle) and emits light (yellow lightning bolt). (Right) In the presence of LNA gapmer
(teal/mauve), translation is inhibited, less luciferase is produced, less luciferin is converted to oxy-
luciferin and less light is emitted. (B) A chart showing the relative luminescence in the presence of
0 nM, 0.5 nM, 5 nM or 50 nM LNA gapmer A1, A2, B1, B2 or Scrambled LNA gapmer. Data have
been normalised to the total luminescence observed in the absence of LNA gapmer. Data are the
average of three experimental repeats and error bars represent the SEM.
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Figure 4. LNA gapmers stimulate RNase H-mediated cleavage of the translation initiation region
of E. coli rne mRNA. Representative denaturing urea-PAGE analysis of RNase H cleavage assays
performed in the presence of increasing concentrations of LNA gapmer as described in Materials
and Methods. (A) LNA gapmers A1 and A2. (B) LNA gapmers B1 and B2. (C) Scrambled LNA
gapmer. The contrast in the images has been adjusted to aid visualisation. The minimal E. coli rne
mRNA was present at 50 nM, where indicated (+). The LNA gapmers were present at the indicated
concentration. RNase H was present at a concentration of 0.008 U/µL, where indicated (+). Note that
the cleavage products migrate at or near the visible dye front. For this reason, we focused on the
disappearance of the band representing the intact minimal E. coli rne mRNA. Plots of the percentage
of intact minimal E. coli rne mRNA remaining at the end of the RNase H cleavage assay against LNA
gapmer concentration are shown in (A) LNA gapmers A1 and A2 and (B) LNA gapmers B1 and B2.
Data are the mean from three experimental repeats and error bars represent the SEM. Data were fit
(solid line) to a four-parameter logistic function as described in Materials and Methods.
As can be seen from the gels in Figure 4, the amount of intact minimal E. coli rne mRNA
remaining at the end of the assay decreased with increasing concentration of LNA gapmer
for LNA gapmers A1, A2, B1 and B2 (Figure 4A,B). This suggests that these gapmers all
recruit RNase H to the minimal E. coli rne mRNA and facilitate RNase H-mediated cleavage
of the mRNA. Efficient mRNA cleavage only occurred in the presence of both LNA gapmer
and RNase H (Figure 4A,B). In contrast, no cleavage of the minimal E. coli rne mRNA was
observed in the presence of Scrambled LNA gapmer, even at the highest LNA gapmer
concentration (100 nM) tested (Figure 4C).
In order to try to quantitate the effect of the different LNA gapmers on RNase H
recruitment and RNase H-mediated mRNA cleavage, the data for LNA gapmers A1, A2,
B1 and B2 were fit to a four-parameter logistic function (Figure 4A,B) which allowed us to
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estimate the half maximal inhibitory concentration (IC50) for each of them. When referring
to this as inhibition, we considered cleavage of the minimal E. coli rne mRNA to represent
inhibition of mRNA function. This analysis suggested that LNA gapmer A1, with an IC50
of 0.4 ± 0.1 nM, was the most effective of all of the LNA gapmers to recruit RNase H and
stimulate RNase H-mediated cleavage of the minimal E. coli rne mRNA. The IC50 for LNA
gapmer A2, at 10.5 ± 2.8 nM, was approximately 25-fold higher than for LNA gapmer A1.
Since LNA gapmers A1 and A2 have the same nucleotide sequence, this implies that the
difference is a consequence of the 3-10-3 LNA gapmer configuration of LNA gapmer A1
compared to the 4-10-4 LNA gapmer configuration of LNA gapmer A2. However, this
trend between the 3-10-3 and 4-8-4 LNA gapmer configurations was less apparent for the
LNA gapmer B sequence with IC50s of 4.2 ± 1.9 nM for the 3-10-3 LNA gapmer B1 and
8.0 ± 2.9 nM for the 4-8-4 LNA gapmer B2.
3. Discussion
Increasing antibacterial resistance has led to a need for novel antibacterial targets
and novel antibacterial strategies. RNase E/rne has been identified as a prospective
antibacterial target [3,4] while antisense oligonucleotides hold potential as an antibacterial
strategy [14–17]. In this study we combined both of these novel factors to target rne mRNA
with antisense oligonucleotides. Specifically, we have successfully designed two antisense
oligonucleotide sequences to target E. coli rne mRNA and have demonstrated that they
have the requisite translation blocking activity and the ability to recruit RNase H and
facilitate mRNA cleavage in vitro. This work provides the foundation for the development
of an antibacterial strategy targeting RNase/rne.
The earliest antisense oligonucleotides targeted viral RNAs [21,22]. This pioneering
work highlighted the potential of antisense approaches to rationally target essentially any
RNA to combat a variety of infections and/or diseases. Although there has been significant
progress in the development of therapeutic antisense oligonucleotides to target disease, such
as neurodegenerative disorders, cardiovascular disorders and cancer (reviewed in [23–25]),
antisense oligonucleotides for antibacterial applications are yet to make it to the clinic.
One of the main reasons why antibacterial antisense oligonucleotide research lags behind
other RNA therapeutics is the challenge of cellular uptake [17]. There has been far less
focus on antisense oligonucleotide delivery to bacterial cells than to eukaryotic cells, and
the advances that have been made in the eukaryotic field are not broadly applicable to
prokaryotic systems [17]. Due to the known challenges with antisense oligonucleotide
delivery to bacterial cells, it is best practice to investigate the plausibility of targeting a
bacterial mRNA target with antisense oligonucleotides in vitro in the first instance [17],
just as we have done here for E. coli rne mRNA.
Indeed, our results demonstrate that it is feasible to target E. coli rne mRNA with
antisense oligonucleotides. In addition, our comparison of different antisense oligonu-
cleotide sequences, different LNA gapmer configurations and different modes-of-action
of the LNA gapmers has provided some key knowledge to take forwards into in vivo
studies. As might have been expected, the LNA gapmer A sequence which targets both
the RBS and start codon of the E. coli rne mRNA translation initiation region was more
efficient at inhibiting translation than the LNA gapmer B sequence which only targets the
start codon (Figure 3). It is possible that preventing ribosome binding may be a better
strategy than blocking ribosome progression. However, this result may simply reflect the
different binding affinities observed for the LNA gapmer A and B sequences (Figure 2).
The origin of these different binding affinities is unclear. It is known that the structural
context of the antisense oligonucleotide binding site is a critical determinant for its binding
affinity [26]. However, translation initiation regions of mRNAs are typically unstructured
to allow access to ribosomes [17] and the E. coli rne mRNA translation initiation region
has been reported to be unstructured [19]. Therefore, there is no obvious difference in the
structural context of the binding site for LNA gapmer A compared to LNA gapmer B.
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The comparison of the 3-10-3 and 4-8-4 LNA gapmer configurations generated mixed
results. There were hints that the 4-8-4 LNA gapmer configuration performed better
with regard to inhibiting translation (Figure 3). This might be explained by the increased
LNA content stabilising the mRNA:LNA gapmer complex. In contrast, the 3-10-3 gapmer
configuration appeared to perform better with regard to RNase H recruitment and mRNA
cleavage (Figure 4). This might be explained if either the higher DNA content of 3-10-3 LNA
gapmers enhances RNase H recruitment, or the lower binding affinity of the 3-10-3 LNA
gapmers leads to higher LNA gapmer recycling, relative to the 4-8-4 LNA gapmers [27].
Interestingly, although there may be preferred sequences and/or LNA gapmer config-
urations, our findings suggest that antisense oligonucleotides can efficiently down-regulate
rne mRNA expression by either sterically blocking translation or stimulating RNase H-
mediated mRNA cleavage. The majority of antisense oligonucleotides that have been
reported to have antibacterial activity are either entirely PMO or entirely PNA (Supple-
mentary Table S1), are not recognised by RNase H, and are therefore restricted to down-
regulating gene expression by sterically blocking translation. This is in contrast to wider
RNA therapeutic applications where the value of combining oligonucleotide chemistries,
e.g., as gapmers, to optimise antisense oligonucleotide properties and mode-of-action is
now recognised [17,18,23]. Incompatible assay conditions meant that, unfortunately, we
were unable to test the effect of combining the two modes of action and it remains to be
seen whether there is a preferred mode-of-action in vivo.
Having demonstrated the successful targeting of E. coli rne mRNA with antisense
oligonucleotides in vitro, the next step would be to investigate their activity, particularly in
regard to their antibacterial properties, in vivo. As discussed above, delivery of antisense
oligonucleotides to bacterial cells is challenging [17] and a “naked” LNA gapmer would
not be expected to enter bacterial cells. Not surprisingly, preliminary Kirby-Bauer disk
diffusion assays [28] with LNA gapmers A1 and A2, and E. coli, showed no inhibition of
bacterial growth. The most common strategy for facilitating antisense oligonucleotide
delivery is the conjugation of a cell-penetrating peptide (CPP), e.g., (KFF)3F [17,29–33],
to the antisense oligonucleotide. This strategy has been used to deliver PNA antisense
oligonucleotides into E. coli [29] and LNA antisense oligonucleotides into Staphylococcus
aureus [32] and would, therefore, be a good place to start for the E. coli rne mRNA-targeting
LNA gapmers. Alternative strategies, such as the use of nanomaterials, are rarely used for
antibacterial antisense oligonucleotides [17]. Although, progress is being made in terms of
using cationic vesicles (bolasomes) to deliver antisense oligonucleotides into Clostridium
difficile [34]. Cellular uptake could be confirmed by using a fluorescently labelled CPP-LNA
gapmer and confocal microscopy [17].
It would also be interesting to investigate whether the antisense oligonucleotides
designed here to target E. coli rne mRNA could be effective against rne mRNA from
other bacterial species. Small molecule inhibitors of E. coli RNase E also inhibited RNase
E from other bacteria suggesting potential as lead compounds in the development of
broad spectrum antibiotics [12,13]. As shown in Figure 5, the region where the LNA
gapmers A1 and A2 bind to E. coli rne mRNA, is absolutely conserved in the rne mRNA
of the closely related bacterium S. enterica. However, in another closely related bacterium,
Y. pestis, there is sequence variation. This sequence variation becomes more pronounced in
more distantly related bacteria such as Francisella tularensis, Acinetobacter baumannii and
Burkolderia pseudomallei. In contrast, the rne translation region in Mycobacteriun tuberculosis
is similar to that in E. coli. Experimental validation will be needed to ascertain how much
sequence variation can be tolerated before an LNA gapmer fails to have an effect. This will
be important for tailoring antibacterial strategies and also for combatting the emergence of
antibacterial resistant mutants.
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Figure 5. Sequence alignment of the −21 to +3 translation initiation region of rne mRNA. A sequence
alignment of the −21 to +3 translation initiation region of the rne mRNA from Escherichia coli,
Salmonella enterica, Yersinia pestis, Francisella tularensis, Acinetobacter baumannii, Burkolderia pseudomallei
and Mycobacterium tuberculosis. Sequences were aligned using MAFFT [35] and coloured by nucleotide
in JalView [36]. The complementary LNA gapmer A sequence is shown above the alignment to
indicate the LNA gapmer A1/A2 binding site.
In summary, we have successfully designed two novel antisense oligonucleotide
sequences to target E. coli rne mRNA, a novel antibacterial target. We synthesised four LNA
gapmers based on these sequences and demonstrated that they bind to E. coli rne mRNA,
inhibit translation of E. coli rne mRNA and facilitate RNase H recruitment and mRNA
cleavage in vitro. Given these activities, it is anticipated that these LNA gapmers will
display antibacterial activity in vivo. Although the challenge of antisense oligonucleotide
delivery remains, there are feasible strategies available. Therefore, this work provides the
foundation for a possible novel antibacterial strategy targeting rne mRNA.
4. Materials and Methods
4.1. LNA Gapmer Design and Synthesis
Two 16-mer antisense oligonucleotide sequences (sequence A: 5′ CATCGTAACT-
TACTCA 3′; sequence B: 5′ GCGTTTCATCGTAACT 3′) were designed to target the −30 to
+15 translation initiation region of the E. coli rne gene (5′ CGUCAAUGUAAGAAUAAU-
GAGUAAGUUACGAUGAAACGCAUGCUG 3′). Each sequence was synthesised as an
LNA3-DNA10-LNA3 3-10-3 gapmer (LNA gapmer A1/B1) and as an LNA4-DNA8-LNA4
4-8-4 gapmer (LNA gapmer A2/B2). The oligonucleotides were synthesised under standard
conditions at 1 µmol scale using an ABI 394 DNA Synthesizer (Biolytic Lab Performance,
Fremont, CA, USA) on 1000 Å UnyLinker-functionalised LCAA CPG support. The oligonu-
cleotides were subsequently cleaved from support and the Unylinker moiety and protecting
groups were removed by treatment with concentrated aqueous ammonia at 55 ◦C overnight.
The solution was decanted and dried using a centrifugal evaporator, then the pellets were
diluted in 1 mL milliQ water and purified using ion exchange HPLC. The oligonucleotides
were characterised using LC-MS (ESI-mode) and the concentration of the final solutions
was determined according to their absorbance at 260 nm.
A scrambled 16-mer sequence (5′ ATCTACCAAATTTCCG 3′) was also generated
based on sequence A using Shuffle DNA [37]. This sequence was synthesised at 0.05
µmole scale as an LNA3-DNA10-LNA3 3-10-3 gapmer (Scrambled LNA gapmer) and
HPLC-purified by Merck (Merck Life Science UK Limited, Gillingham, UK).
4.2. Design and Synthesis of a Minimal E. coli rne mRNA
A 3′ 6-fluorescein amidate (FAM)-labelled RNA oligonucleotide corresponding to the
−30 to +15 translation initiation region of the E. coli rne gene (RNA; 5′ CGUCAAUGUAA-
GAA UAAUGAGUAAGUUACGAUGAAACGCAUGCUG-[FAM] 3′) was synthesised at
1 µmole scale and HPLC-purified by Sigma-Aldrich (now Merck Life Science UK Limited).
The concentration of FAM-labelled RNA was determined according to the absorbance
at 260 nm using a conversion factor of 0.26 to correct for the 6-FAM absorbance [38].
Denaturing urea-PAGE was used to confirm that the RNA was a single species of the
expected size.
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4.3. Electrophoretic Mobility Shift Assays (EMSAs)
A 10× (500 nM) stock of minimal E. coli rne mRNA was prepared in EMSA reaction
buffer (10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 50 mM KCl, 0.5 mM ethylenediamineter-
traacetic acid (EDTA), 10% glycerol), heated at 80 ◦C for 10 min, cooled at room temperature
for 10 min and then equilibrated at 37 ◦C for 10 min. 10× stocks of each of the LNA gap-
mers were prepared at concentrations of 25 nM, 50 nM, 250 nM, 500 nM, 2.5 µM and 5 µM
in EMSA reaction buffer and equilibrated at 37 ◦C for 10 min. 10 µL reaction mixtures
containing 50 nM minimal E. coli rne mRNA and 0 nM, 2.5 nM, 5 nM, 25 nM, 50 nM,
250 nM or 500 nM LNA gapmer in EMSA reaction buffer were assembled and incubated
at room temperature for 10 min. Reactions were analysed by 12% native-PAGE run in
Tris-borate-EDTA (TBE) running buffer at 80 V for 2 h at room temperature. Gels were
visualised using a GBox UV transilluminator (Syngene, a division of Synoptics Ltd., Cam-
bridge, UK). Digitised images were quantitated using ImageJ (Rasband, W.S., ImageJ, U.S.
National Institutes of Health, Bethesda, MD, USA, https://imagej.nih.gov/ij/, 1997–2018)
and the percentage of bound and unbound RNA in each lane was calculated. Data from
triplicate experiments were fit in Grafit5 (Erithacus Software, Grinstead, West Sussex, UK)





In this equation, y is the percentage of FAM-labelled RNA bound by LNA gapmer, [L]
is the concentration of LNA gapmer, n is the slope factor, Cap is the theoretical maximal
amount of FAM-labelled RNA than can be bound by LNA gapmer, K is the apparent
equilibrium dissociation constant (also termed apparent Kd) and background allows for any
y-axis displacement from the origin.
4.4. Cell-Free Reporter Assay
4.4.1. Design and Synthesis of the E. coli rne-Firefly Luciferase (luc) Reporter Plasmid
A translational fusion of the −397 to +30 region of E. coli rne and the coding region
of the firefly luciferase (luc) gene (Supplementary Figure S3) was synthesised by GeneArt
(Thermo Fisher Scientific, Waltham, MA, USA) and ligated between the XbaI and XhoI
restriction sites of pET28b (Novagen, a brand of Merck, Darmstadt, Germany) to generate
pET28[rne-luc]. The sequence was confirmed by DNA sequencing. E. coli DH5α was
transformed with pET28[rne-luc]. DH5α, pET28[rne-luc] was grown in LB supplemented
with 25 µg/mL kanamycin at 37 ◦C overnight with shaking. Cells were harvested by
centrifugation and pET28[rne-luc] was extracted using the NucleoBond Xtra Midi plasmid
preparation kit (Macherey-Nagel, Düren, Germany).
4.4.2. In Vitro Transcription-Translation Real-Time Reporter Assay
In vitro transcription-translation of pET28 [rne-luc] was performed using the E. coli
T7 S30 Extract System for Circular DNA (Promega, Madison, WI, USA). 50 µL reactions
were prepared in a 96-well plate. Each reaction contained 750 ng pET28 [rne-luc], 1 mM
luciferin (BD Biosciences, BD Biosciences, San Jose, CA, USA), 5 µL Complete Amino Acid
Mixture, 20 µL S30 Premix and 15 µL T7 S30 Extract. The reactions were supplemented with
0.5 nM, 5 nM or 50 nM LNA gapmer, as indicated. The reactions were not supplemented
with exogenous RNase H. Reactions were incubated at 37 ◦C for 2 h in a Hidex Sense
plate-reader (Hidex Ltd., Turku, Finland). The luminescence (or luciferase signal) was
recorded every 2.5 min for a total of 120 min. The total luciferase signal for each LNA
gapmer concentration (0 nM, 0.5 nM, 5 nM and 50 nM) was quantitated by integrating the
area under the curve using a trapezoid method in Excel. Integrated values were normalised
to a percentage (relative to the total luciferase signal in the absence of LNA gapmer) and
plotted as a bar chart in Grafit5.
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4.5. RNase H Cleavage Assay
Twenty five µL reaction mixtures containing 50 nM minimal E. coli rne mRNA and
0 nM, 2.5 nM, 5 nM, 25 nM, 50 nM or 100 nM LNA gapmer in 1× RNase H Reaction Buffer
(NEB, Ipswich, MA, USA; 75 mM KCl, 50 mM Tris-HCl pH 8.3, 3 mM MgCl2, 10 mM DTT)
were assembled and incubated at 37 ◦C for 5 min to allow LNA gapmer to bind to the target
minimal E. coli rne mRNA and form the RNase H substrate. RNase H, equilibrated at 37 ◦C,
was then added to a final concentration of 0.008 U/µL. The complete reaction mixture
was incubated at 37 ◦C for a further 45 min. Reactions were terminated by the addition
of 0.5 volumes of quench buffer (95% (v/v) formamide, 18 mM EDTA). Reaction mixtures
were heated at 95 ◦C for 5 min and reaction products were resolved by 8% denaturing
urea-PAGE. Gels were visualised using a GBox UV transilluminator (Syngene, a division
of Synoptics Ltd., Cambridge, UK). Digitised images were quantitated using ImageJ and
the percentage of cleaved and uncleaved FAM-labelled RNA in each lane was calculated.
Data from triplicate experiments were fit to a four-parameter logistic function to estimate







)s + background (2)
In this equation, y is the percentage of intact FAM-labelled RNA at LNA gapmer
concentration x; Range is the theoretical extent of the reaction, IC50 is the concentration of
LNA gapmer at half the Range, s is the slope factor and background allows for any y-axis
displacement from the origin.
Supplementary Materials: The following are available online, Supplementary References, Supple-
mentary Table S1: Examples of antibacterial antisense oligonucleotides, Supplementary Figure S1:
Mode-of-action of antisense oligonucleotides, Supplementary Figure S2: Unmodified nucleic acids
and examples of chemical analogues used in antisense oligonucleotides, Supplementary Figure S3:
The E. coli rne-firefly luciferase reporter.
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